Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
- Conditions
- Hepatitis C
- Interventions
- Genetic: Interleukin 28B genotype
- Registration Number
- NCT01429155
- Lead Sponsor
- Henry Ford Health System
- Brief Summary
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients.
There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
- Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older
- Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older
- Patients who are not willing to sign the consent
- Inability to obtain liver specimen (recipients)
- Inability to obtain blood sample (donors)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Liver transplant recipeints Interleukin 28B genotype Patients suffering from chronic hepatitis C that required a living donor liver transplant. Liver Donors Interleukin 28B genotype Patients who donated part of their liver to a patient suffering from chronic hepatitis C
- Primary Outcome Measures
Name Time Method Sustained virological response after living donor liver transplant 12-24 months Determine if sustained virological response is achieved after liver transplantation for hepatitis C with antiviral therapy (rivabirin and pegelated interferon) based on patient IL28B genotype
- Secondary Outcome Measures
Name Time Method Liver retransplantation 1-24 months Determine the need of liver retransplantion based on the IL 28B genotype
Trial Locations
- Locations (1)
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States